Anebulo Pharmaceuticals I... (ANEB)
1.65
0.01 (0.61%)
At close: Jan 15, 2025, 11:00 AM
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
| Year | FY24 | FY23 | FY22 | FY21 | FY20 |
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | n/a | n/a | n/a | n/a | n/a |
| Gross Profit | n/a | n/a | n/a | n/a | n/a |
| Operating Income | -8.31M | -11.78M | -6.83M | -3.61M | -173.35K |
| Interest Income | 97.79K | 92.41K | 7.33K | 1.02K | 7.72 |
| Pretax Income | -8.20M | -11.73M | -6.83M | -30.25M | -174.64K |
| Net Income | -8.20M | -11.73M | -6.81M | -30.26M | -174.64K |
| Selling & General & Admin | 4.76M | 6.18M | 3.87M | 1.34M | 23.35K |
| Research & Development | 3.55M | 5.60M | 2.96M | 2.27M | 150.00K |
| Other Expenses | n/a | -41.15K | -1.78K | -1.34K | n/a |
| Operating Expenses | 8.31M | 11.78M | 6.83M | 3.61M | 173.35K |
| Interest Expense | n/a | n/a | 7.33K | 11.77K | 1.29K |
| Selling & Marketing Expenses | 4.80K | n/a | n/a | n/a | 23.21K |
| Cost & Expenses | 8.31M | 11.78M | 6.83M | 3.61M | 173.35K |
| Income Tax | n/a | -104.19K | -12.89K | 10.75K | -1.04K |
| Shares Outstanding (Basic) | 25.82M | 25.07M | 23.34M | 23.34M | 23.72M |
| Shares Outstanding (Diluted) | 25.82M | 25.07M | 23.34M | 23.34M | 23.72M |
| EPS (Basic) | -0.32 | -0.47 | -0.29 | -1.3 | -0.01 |
| EPS (Diluted) | -0.32 | -0.47 | -0.29 | -1.3 | -0.01 |
| EBITDA | -8.05M | -11.78M | 5.55K | -30.24M | -173.35K |
| Depreciation & Amortization | 258.28K | 11.78M | 6.83M | 3.61M | 1.04M |